Paracetamol Market 2025: DOLO-650 the Top Prescribed brand, suggests industry data
New Delhi: Micro Labs' flagship paracetamol brand, DOLO-650, has cemented its position as the top-selling paracetamol in the country with sales of Rs 311.7 crore in Moving Annual Total (MAT) July 2025, according to the IQVIA SSA Data MAT July 2025. Dolo-650's position also stands as the highest prescribed brand accounting for 0.66% of total prescriptions in the country during Nov 2024-Feb 2025, as per C MARC CPR (Current Medical Audit of Retail Chemists - Current Prescription Research).
As per the data reviewed by Medical Dialogues, DOLO-650 not only maintained its lead in sales but also showed a turnaround in value growth, indicating growing preference among prescribers.
The IQVIA data claimed that the total value of the paracetamol 650mg market reached Rs 624.2 crore for the 12 months ending July 2025, with DOLO-650 holding the No. 1 rank and commanding almost half of this segment. The brand recorded sales of Rs 311.7 crore in MAT July 2025, posting a modest growth of 0.5% and rebounding from a 9.53% decline in the prior year. Meanwhile, its nearest competitor, CALPOL, registered sales of Rs 135.4 crore in MAT July 2025.
According to prescription share data from C-MARC, a widely used pharma prescription audit, DOLO-650 retained its top spot as the most prescribed brand in the country with a 0.66% prescription share in Nov–Feb 2025, compared to 0.69% in Nov–Feb 2024, while CALPOL-650 ranked third with 0.53%, compared to 0.52% in the same period last year. Broader market trends point to shifting prescription preferences—brands like PAN and PAN-D from Alkem continue to feature prominently, while ZERODOL SP registered strong year-on-year growth, signalling evolving competitive dynamics in the prescription space.
In the paracetamol 650mg market, DOLO-650 continued to consolidate its leadership over the past year. As per SSA MAT July 2025 data, DOLO’s market share in the segment grew from 49% in MAT July 2023 to 50% in MAT July 2025. This steady growth, coupled with its strong prescription share, helped reinforce its position as the segment leader.
